Stockscreener 앱 받기
132.57
0.16%
0.21
시장 영업 전:
134.20
1.63
+1.23%
전일 마감가:
$132.36
열려 있는:
$132.37
하루 거래량:
1.17M
Relative Volume:
0.71
시가총액:
$254.37B
수익:
$54.45B
순이익/손실:
$14.42B
주가수익비율:
18.08
EPS:
7.333
순현금흐름:
$17.15B
1주 성능:
+0.31%
1개월 성능:
+0.21%
6개월 성능:
+9.77%
1년 성능:
+34.47%
1일 변동 폭
$131.77
$133.01
1주일 범위
$129.98
$133.84
52주 변동 폭
$96.06
$134.24
노바티스 ADR Stock (NVS) Company Profile
NVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-09-12 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-08-08 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Underweight |
| 2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 재개 | Citigroup | Buy |
| 2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
| 2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 개시 | Bernstein | Mkt Perform |
| 2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
| 2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 재확인 | Leerink Partners | Outperform |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Insider Monkey
Novartis (NVS) enters $1.7 billion development deal, says report - MSN
Price Over Earnings Overview: Novartis - Sahm
Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease - Benzinga
13 Best ADR Stocks to Invest In - Insider Monkey
Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Finviz
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Sahm
Novartis AG (NVS) Announces US FDA Approval of Itvisma - Finviz
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Sahm
Baird Financial Group Inc. Cuts Holdings in Novartis AG $NVS - Defense World
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Free cash flow per share of Novartis AG Sponsored ADR – GETTEX:NOTA - TradingView
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz
Why Novartis Stock Topped the Market Today - sharewise.com
Novartis AG Common Stock (NYSE:NVS) Stock Quote - Markets Financial Content
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults - Sahm
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN) - The Globe and Mail
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm
Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail
Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India
Novartis completes acquisition of Tourmaline Bio - Novartis
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm
Novartis announces expiration of Tourmaline Bio tender offer - Novartis
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
0.22%
자본화:
|
볼륨(24시간):